reduce prescription costs
Reduce prescription drug costs.
Occurrences
Evidence
Representatives Marcy Kaptur, Ro Khanna, Anna Paulina Luna, and Andy Biggs introduced the bipartisan Global Fairness in Drug Pricing Act to codify the core provisions of President Trump’s Executive Order into law. The release says the bill would 'reduce prescription drug prices' and 'align U.S. drug prices with international benchmarks' by directing HHS to propose rulemaking that imposes most-favored-nation price targets.
Congress.gov lists H.R. 3493 as introduced on 05/19/2025. The bill title is 'Global Fairness in Drug Pricing Act,' and its official title is 'To reduce prescription drug prices by aligning U.S. prices with international benchmarks.' The bill was referred to committee and the latest action shown is introduction and referral.
HHS announced on May 20, 2025 that it was taking immediate steps to implement President Trump’s Executive Order on most-favored-nation prescription drug pricing and had identified specific targets pharmaceutical manufacturers are expected to meet. The release states these commitments would ensure Americans no longer pay more for medications than patients in comparable countries.
CMS announced eligible Medicare beneficiaries will be able to access certain GLP-1 medications for $50 per month beginning July 1, 2026, through December 31, 2027.
Kaptur voted to pass H.R. 7148, the Consolidated Appropriations Act, 2026, which the release says includes funding for the Department of Health and Human Services among other agencies. The statement focuses on health funding and community projects, not a specific prescription-drug-cost reduction mechanism.
Assessments
Kaptur made a clear, substantive effort on the promise by introducing and backing H.R. 3493, the Global Fairness in Drug Pricing Act, which explicitly aimed to reduce prescription drug prices. However, the bill was only introduced and referred to committee, with no evidence it became law or directly delivered lower prices through her action. Broader federal steps on Medicare GLP-1 pricing and HHS most-favored-nation policy show movement in the promised direction during the same term, but those outcomes were executive-branch actions not primarily attributable to Kaptur. That supports partial credit for contributing effort and policy alignment, but not full delivery.